neuroendocrine tumor
Novartis Eyes on First-Line Radiotherapy Role for Lutathera Following Triumph in Neuroendocrine Tumors Trial
Anika Sharma
Over half a decade since its inaugural FDA approval, Novartis is championing promising trial outcomes for Lutathera, positioning it as ...
